Global Uric Acid Drugs Market Size, Share and Trends Analysis, By Drug (Allopurinol, Febuxostat, Probenecid), By Distribution Channel (Online Pharmacies, Retail Pharmacies, and Hospital Pharmacies), Forecast (2022-2028)

The global uric acid drugs market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Uric acid is a waste product found in the blood. It is created when the body breaks down chemicals called purines. Most uric acid dissolves in the blood pass through the kidneys and leaves the body through urine. Food and drinks which are high in purines also increase the level of uric acid. An excess of uric acid leads to the formation of crystals in the body, which eventually leads to the deposition of uric acid crystals in joints, resulting in inflammation and pain.  Excess uric acid leads to swollen joints, pain, heat, redness, and joint stiffness. Symptoms start with the inflammation of the big toe. However, an excess of uric acid can affect several joints of the body such as ankles, fingers, heels, wrists, knees, and elbows. These kinds of symptoms are more seen in men compared to women. These factors are driving the growth of the global uric acid drugs market.

The market is segmented based on the drug and distribution channel. Based on the drug, the market is sub-segmented into Allopurinol, Febuxostat, and Probenecid. Allopurinol is used to prevent or lower high uric acid levels in the blood. It is also used to prevent or lower excess uric acid levels caused by cancer medicines or in patients with kidney stones. Febuxostat is in a class of medications called xanthine oxidase inhibitors. It works by decreasing the amount of uric acid that is made in the body. Probenecid is used in the treatment of chronic gout or gouty arthritis. These conditions are caused by too much uric acid in the blood. The medicine works by removing the extra uric acid from the body.

Some major players in the market include AstraZeneca plc, Boehringer Ingelheim International GmbH, and GlaxoSmithKline plc, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Drug
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- AstraZeneca plc, Boehringer Ingelheim International GmbH, and GlaxoSmithKline plc, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Uric Acid Drugs Market Report by Segment

By Drug

• Allopurinol
• Febuxostat
• Probenecid

By Distribution Channel

• Online Pharmacies
• Retail Pharmacies
• Hospital Pharmacies

Global Uric Acid Drugs Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa